E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Stitching neck of the womb (cervix) to help prevent premature labour/delivery. |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10054992 |
E.1.2 | Term | Cervix cerclage procedure |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10041536 |
E.1.2 | Term | Spinal anaesthesia |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine if subarachnoid hyperbaric 2% prilocaine produces a clinically meaningful reduction in time taken for regression of lower limb motor block when compared to hyperbaric 0.5% bupivacaine |
|
E.2.2 | Secondary objectives of the trial |
To compare the intraoperative characteristics of the subarachnoid block and quality of intraoperative anaesthesia in the two groups. To compare the recovery profiles in the two groups To compare the incidence of complications in the two groups To compare the satisfaction of the participants in each group
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Healthy (ASA score 1 or 2) women in the second trimester of pregnancy presenting for elective cervical cerclage under SAB. • Age > 18 years
|
|
E.4 | Principal exclusion criteria |
• Inability to read or understand the patient information sheet (PIS) • Age < 18 years • Unable or unwilling to consent to participation • non-elective procedure • serious co-morbidities (ASA score 3 or above) • any contraindication to SAB, e.g. local or generalised infection, active central nervous system disease, coagulation disorders or anti-coagulant medication • any history of allergic reaction to any of the medications in the protocol • concomitant use of class III anti-arrhythmics (sulfonamides, antimalarials, sodium nitroprussate, nitroglycerin, other local anaesthetics) • any contraindication to the use of bupivacaine or prilocaine as listed in the SmPCs.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The time taken in minutes from initiation of subarachnoid block (SAB) until regression of motor block as assessed using the Bromage score of I |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Intraop - 0, 5, 10, 15 and 20 mins Postop - every 15 mins |
|
E.5.2 | Secondary end point(s) |
• Mean time in minutes until achievement of loss of cold sensation to ethyl chloride spray at the tenth thoracic dermatomal level (T10) • Mean time in minutes until achievement of complete motor block, assessed as Bromage score = IV. • Uppermost (cephalad) dermatomal level of sensory block as measured by loss of cold sensation to ethyl chloride spray at 20 minutes (mean). • Mean degree of motor block as assessed on the Bromage scale at 20 minutes. • Administration of hypnotic agent (proportion of cases). • Administration of analgesic agent (proportion of cases). • Mean pain score on the NRS of maximal discomfort experienced during the procedure • Mean time in minutes from SAB to ambulation • Mean time in minutes from SAB to micturition • Mean time in minutes from SAB to discharge • Proportion of cases experiencing hypotension > 10% SBP drop from baseline). • Proportion of cases experiencing bradycardia (< 45 bpm) • Proportion of cases experiencing nausea or vomiting • Proportion of cases requiring urethral catheterisation • Proportion of cases experiencing TNS • Proportion of cases experiencing backache • Proportion of cases experiencing headache • Mean level of patient satisfaction as assessed by a Numerical Rating Score (NRS, 0-10).
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |